SURGICAL HEART VALVES

MECHANICAL HEART VALVES

Unique design features have established Abbott mechanical heart valves—including the Regent™ and Masters Series—as a gold standard for reliability and performance, while maintaining low complication rates over the long term.

SURGICAL HEART VALVES

MECHANICAL HEART VALVES

Unique design features have established Abbott mechanical heart valves—including the Regent™ and Masters Series—as a gold standard for reliability and performance, while maintaining low complication rates over the long term.

CONFIDENTLY IMPLANT THE MOST TRUSTED AORTIC AND MITRAL MECHANICAL VALVES IN THE WORLD

  • Design-driven hemodynamic confidence & low thrombogenicity

    Abbott mechanical heart valves lead the way with a proven bileaflet design that results in low thrombogenicity and excellent patient outcomes.

    • Leaflets open to an 85-degree angle in systole due to their upstream positioning, enabled by unique pivot guards (shown at right)
    • Strong, uniform velocities within hinge recesses aid washout of blood elements3
    • Low carbon surface area means less thrombus formation
    • Orifice-to-annulus ratio (as high as 84%) ensures large effective orifice areas (EOAs) and reduces prosthesis-patient mismatch4
  • Unique Design Features

    The Pivot Guard Design 
    An Abbott Hallmark

    Featured in all Abbott Mechanical Heart Valves, the Pivot Guard offers benefits both during implant and post-implant

    • Recessed design minimizes interaction with sub-annular native mitral valve apparatus
    • Minimized carbon surface area can lessen thrombus formation
    • Pivot guards help shield pivot mechanism from pannus ingrowth
    • Enables a consistent 85-degree opening angle, promoting minimized leaflet flutter and more laminar flow through the orifice5

    Low Thrombogenicity 
    A Necessity in MHV Replacements

    Designed with Low Thrombogenicity at the Forefront

    • Large internal diameters up to 26.1 mm available promote low pressure gradients6
      • Low gradients can help minimize shear stress and thrombogenicity7
    • Uniform velocities within hinge recesses help aid washout of blood elements3
      • Abbott hinge design enables complete leaflet sweep, further aiding washout
         

Abbott Mechanical Heart Valves:
A Gold Standard

Excellent function and durability throughout a patient’s lifetime

Although the prevalence of mitral valve disease is 2 to 3 times higher than aortic valve disease, aortic valve surgeries (excluding transcatheter procedures) are performed 1.6 times more commonly than mitral valve surgeries. The undertreatment of mitral valve disease may be related to the slower progression of symptoms compared with aortic disease, as well as a potential lack of adherence to guidelines for intervention.8

  • Aortic Stenosis (AS) AHA/ACC Treatment Guidelines

    Severe AS presents with exertional dyspnea, syncope, angina, and progression to heart failure. Early intervention produces a better outcome in preventing the clinical deterioration of AS.2 Severe AS affects 3.4% of the population over 60 years of age.9

    Surgical aortic valve replacement (SAVR) is recommended for symptomatic patients with severe AS (Stage D) and asymptomatic patients with severe AS (Stage C) who meet an indication for AVR when surgical risk is low or intermediate. Outcomes after SAVR are excellent in patients who do not have a high procedural risk, resulting in improved survival rates, reduced symptoms, and improved exercise capacity.10
     

    Choosing a Regent™ Mechanical Heart Valve

    The primary advantages of a Regent™ mechanical valve include durability, since mechanical valves are designed to last a lifetime.8 Mechanical valves also avoid the potential of eventual calcification, which can occur with tissue valves. Furthermore, the excellent hemodynamics of the Regent aortic valve is another advantage to consider.

    However, any mechanical valve confers a thrombogenic potential which could eventually result in embolic stroke. This is mitigated by the requirement that patients adhere to lifelong anticoagulants, such as warfarin, to preclude thrombus formation.

    Bleak prognosis without treatment

    Mortality rates are approximately 25% at 1 year and 50% at 2 years in symptomatic AS patients on medical therapy who do not undergo AVR.11

  • Mitral Regurgitation (MR) AHA/ACC Treatment Guidelines

    MR is the most common valve disease worldwide.5 Intervention for patients with primary MR consists of either surgical mitral valve repair or replacement, with repair preferred over replacement if a successful and durable repair can be achieved. Mitral valve surgery is recommended in10:

    • Symptomatic patients with chronic, severe primary MR (stage D) and left ventricular ejection fraction (LVEF) > 30%
    • Asymptomatic patients with chronic, severe primary MR and LVEF 30%–60% and/or LV end-systolic dimension ≥ 40 mm (Stage C2)
    • Chronic, severe primary MR patients undergoing cardiac surgery for other indications
    • Patients with chronic, severe secondary MR (stages C and D) at the time of other cardiac surgery
       

    Choosing the Masters Series Mitral Mechanical Heart Valve

    The Masters Series mitral mechanical heart valve is intended for use as a replacement valve in patients with a diseased, damaged, or malfunctioning mitral valve. The device may also be used to replace a previously implanted mitral prosthetic valve.

    The primary advantages of a Masters Series mitral mechanical valve include durability, since mechanical valves are designed to last a lifetime.13 Mechanical valves also avoid the potential of eventual calcification, which can occur with tissue valves. The excellent hemodynamics and low thrombogenicity of the Masters Series mitral valve are other advantages to consider.

    However, mechanical valves confer a thrombogenic potential and require long-term anticoagulant therapy to preclude thrombus formation. Ultimately, the choice of mechanical versus bioprosthetic valve replacement for all patients, but especially for those between 50 and 70 years of age, must account for the trade-offs between durability (and the need for reintervention), bleeding, and thromboembolism.10

    Late referral for surgical intervention is associated with reduced survival

    There remains an important and substantial opportunity to decrease long-term mortality in patients with mitral valve disease by following established guidelines and encouraging earlier referral for intervention.8

Addressing an unmet need for high-risk pediatric patients

Only Abbott provides the world's smallest pediatric mechanical heart valve, the 15 mm Masters HP, for aortic and mitral heart valves. Developed to address an unmet need for high-risk pediatric patients who formerly had limited options. The patients who need the valve are usually younger than 1 year old with complex heart defects, have had multiple prior heart surgeries and require a valve replacement.

Meet Sadie: A recipient of the world’s smallest 15 mm Pediatric Mechanical Heart Valve

Diagnosed with a heart condition before birth, Sadie received an Abbott mechanical heart valve that saved her life.

  • Resources to help patients learn more about their condition



    MITRAL REGURGITATION

    Learn more



    SURGICAL MITRAL VALVE REPLACEMENT

    Learn more

    Understanding Mitral Valve Disease

    Read more

    Living with Your Mechanical Heart Valve

    Read more

Regent gives you Implantability Options

LOW VALVE IMPLANT HEIGHT HELPS ENSURE CORONARY OSTIA CLEARANCE


REPLICA SIZING WITH THE 907 SIZER GIVES YOU CONFIDENCE THAT YOU ARE USING THE MOST APPROPRIATELY SIZED VALVE

TWO DISTINCT CUFF TYPES PROVIDE YOU WITH DIFFERENT OPTIONS




FLEXCUFF™

FLEXCUFF™




STANDARD CUFF

STANDARD CUFF

  • The Regent Aortic Valve Features Exceptional Hemodynamics in small aortic root patients15,16,*

    .

    *Measured one-year post-surgery.

Implantability Options with Masters Series

The Masters Series Mechanical Heart Valves are rotatable, bileaflet valves designed for secure implantation. The portfolio includes an expansive range of sizes to help you make the best decisions for your patients and the Hemodynamic Plus™ (HP) models are designed to provide a larger effective orifice area.

THE 15 MM PEDIATRIC HEART VALVES JOIN THE FAMILY OF
17–27 MM MASTERS HP MECHANICAL HEART VALVES AND IS SUITABLE FOR TREATING NEWBORNS AND BABIES

LOW VALVE IMPLANT HEIGHT MINIMIZES INTERFERENCE WITH SUBVALVULAR STRUCTURES
IN THE MITRAL POSITION

TWO DISTINCT CUFF TYPES PROVIDE YOU WITH DIFFERENT OPTIONS




EXPANDED CUFF

EXPANDED CUFF




STANDARD CUFF

STANDARD CUFF

ORDERING INFORMATION


For Regent ordering information
 

Read more


For Masters Series ordering information
 

Read more

MAT-2010286 v2.0 | Item approved for U.S. use only.

Copyright © 2022 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2004021 v13.0  |   Item approved for U.S. use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.